Corentec Co

Corentec Co EBITDA Margin

The EBITDA Margin of Corentec Co (104540.KQ) as of Nov 7, 2026 is 9.26 %. In the previous year, EBITDA Margin was 7.79 % — a change of 18.88% (higher).

EBITDA Margin

9.26 %

YoY

18.88%

Last updated:

EBITDA Margin of Corentec Co is 2025 9.26 % . EBITDA Margin of Corentec Co was 2024 7.79 % . It decreases by 18.88% higher compared to the previous year.

The Corentec Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-73.10 KRW
Jan 1, 2019
11.20 KRW
Jan 1, 2020
12.88 KRW
Jan 1, 2021
11.50 KRW
Jan 1, 2022
16.15 KRW
Jan 1, 2023
15.44 KRW
Jan 1, 2024
7.79 KRW
Jan 1, 2025
9.26 KRW
The Corentec Co EBITDA Margin history
YEAREBITDA MarginYoY
9.26 %+18.88%
7.79 %-49.54%
15.44 %-4.42%
16.15 %+40.45%
11.50 %-10.70%
12.88 %+14.95%
11.20 %-115.33%
-73.10 %+567.85%
-10.95 %-225.07%
8.75 %-15.11%
10.31 %+77.53%
5.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Corentec Co Stock analysis

What does Corentec Co do? Corentec Co., Ltd. manufactures and sells artificial articulations, including hip, knee, and spine products. The company offers hip products under the BENCOX brand, featuring primary systems, hemi-arthroplasty systems, and revision systems such as cementless femoral stems and acetabular cups. Knee products are sold under the LOSPA brand, including fixed and mobile primary knee systems and revision systems. Spine products also carry the LOSPA IS brand, comprising pedicle screws and peek cages. Corentec distributes these products domestically and internationally, targeting healthcare providers and hospitals that require orthopedic solutions. The firm’s revenue comes from the sale of hip, knee, and spine products through its BENCOX, LOSPA, and LOSPA IS brand portfolios. Domestic and overseas markets are key segments, with the company focusing on orthopedic surgeons and medical institutions that purchase these specialized medical devices. Corentec’s product lines are designed for both primary and revision surgeries, catering to a broad range of orthopedic needs in the healthcare sector. Corentec Co., Ltd. serves healthcare providers globally, with its BENCOX brand dominating hip product sales and LOSPA/LOSPA IS covering knee and spine solutions. The company’s distribution strategy emphasizes direct sales to hospitals and medical centers, ensuring consistent product availability for surgical procedures. By maintaining distinct brand identities for each product category, Corentec efficiently targets specific medical specialties within the orthopedic market. Corentec Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Corentec Co stock

EBITDA Margin of Corentec Co is 9.26 % in 2025.

EBITDA Margin of Corentec Co changed from 7.79 % to 9.26 %, representing a 18.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Corentec Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Corentec Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Corentec Co

All Key Metrics — Corentec Co